fingolimod hydrochloride has been researched along with Androgen-Independent Prostatic Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, ML; Chan, SH; Chang, WL; Chou, YL; Guh, JH; Hou, DR; Hsu, JL; Hsu, LC; Leu, WJ; Liu, SP; Swain, ShP; Yu, CC | 1 |
1 other study(ies) available for fingolimod hydrochloride and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Signal Transduction; Small Molecule Libraries; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2016 |